Viewing Study NCT04782258

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 12:20 AM

Ignite Modification Date: 2025-12-25 @ 10:24 PM

Study NCT ID: NCT04782258

Status: RECRUITING

Last Update Posted: 2025-09-30

First Post: 2021-02-19

Is NOT Gene Therapy: False

Has Adverse Events: False

Brief Title: A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module